Neogen Corporation Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price
Neogen Corporation (NEOG) reported Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price of $5.43 per share for the 12-month period ending 2026-05-31, per its 10-K filed 2026-07-30.
Financial Statements › Notes › Share-Based Payment Arrangement › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice · last filed 2026-07-30
- Neogen Corporation share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for the quarter ending 2022-08-31 was $10.75, a 61.21% decline year-over-year.
- Neogen Corporation share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for the quarter ending 2021-08-31 was $27.71, a 42.74% decline year-over-year.
- Neogen Corporation share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for the quarter ending 2020-08-31 was $48.39, a 16.57% increase year-over-year.
- Neogen Corporation share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for the quarter ending 2019-08-31 was $41.51, a 45.14% increase year-over-year.
- Neogen Corporation share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for fiscal 2026 was $5.43, a 62.55% decline from fiscal 2025.
- Neogen Corporation share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for fiscal 2025 was $14.50, a 6.54% increase from fiscal 2024.
- Neogen Corporation share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for fiscal 2024 was $13.61, a 7.92% decline from fiscal 2023.
- Neogen Corporation share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for fiscal 2023 was $14.78, a 35.15% decline from fiscal 2022.
| Period end | Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price 3 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price 6 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price 9 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price 12 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price 12 month as first filed |
|---|---|---|---|---|---|
| 2026-05-31 | $5.43 10-K · filed 2026-07-30 | ||||
| 2025-05-31 | $14.50 10-K · filed 2026-07-30 | ||||
| 2024-05-31 | $13.61 10-K · filed 2026-07-30 | ||||
| 2023-05-31 | $14.78 10-K · filed 2025-07-30 | ||||
| 2022-11-30 | $10.75 10-Q · filed 2023-01-09 | ||||
| 2022-08-31 | $10.75 10-Q · filed 2022-09-30 | ||||
| 2022-05-31 | $22.79 10-K · filed 2024-07-30 | ||||
| 2022-02-28 | $22.69 10-Q · filed 2022-04-01 | ||||
| 2021-11-30 | $22.42 10-Q · filed 2021-12-30 | ||||
| 2021-08-31 | $27.71 10-Q · filed 2021-09-30 | ||||
| 2021-05-31 | $24.38 10-K · filed 2023-08-15 | ||||
| 2021-02-28 | $44910.00 10-Q · filed 2021-03-31 | ||||
| 2020-11-30 | $42.04 10-Q · filed 2020-12-29 | ||||
| 2020-08-31 | $48.39 10-Q · filed 2020-09-30 | ||||
| 2020-05-31 | $20.12 10-K · filed 2022-07-27 | $40.24 10-K · filed 2020-07-30 | |||
| 2020-02-29 | $40.07 10-Q · filed 2020-04-03 | ||||
| 2019-11-30 | $39.01 10-Q · filed 2019-12-27 | ||||
| 2019-08-31 | $41.51 10-Q · filed 2019-09-26 | ||||
| 2019-05-31 | $15.64 10-K · filed 2021-07-30 | $31.28 10-K · filed 2019-07-30 | |||
| 2019-02-28 | $30.76 10-Q · filed 2019-03-29 | ||||
| 2018-11-30 | $29.49 10-Q · filed 2018-12-28 | ||||
| 2018-08-31 | $28.60 10-Q · filed 2018-10-05 | ||||
| 2018-05-31 | $28.18 10-K · filed 2020-07-30 | ||||
| 2018-02-28 | $28.23 10-Q · filed 2018-03-29 | ||||
| 2017-11-30 | $27.50 10-Q · filed 2018-01-05 | ||||
| 2017-08-31 | $31.66 10-Q · filed 2017-09-29 | ||||
| 2017-05-31 | $22.82 10-K · filed 2019-07-30 | $30.42 10-K · filed 2017-07-28 | |||
| 2017-02-28 | $29.04 10-Q · filed 2017-03-31 | ||||
| 2016-11-30 | $28.21 10-Q · filed 2016-12-29 | ||||
| 2016-08-31 | $28.93 10-Q · filed 2016-09-30 | ||||
| 2016-05-31 | $17.60 10-K · filed 2018-07-27 | $23.47 10-K · filed 2016-07-29 | |||
| 2016-02-29 | $23.45 10-Q · filed 2016-03-31 | ||||
| 2015-11-30 | $22.09 10-Q · filed 2016-01-08 | ||||
| 2015-08-31 | $21.08 10-Q · filed 2015-09-30 | ||||
| 2015-05-31 | $16.69 10-K · filed 2017-07-28 | ||||
| 2015-02-28 | $17.04 10-Q · filed 2015-04-01 | ||||
| 2014-11-30 | $15.88 10-Q · filed 2014-12-30 | ||||
| 2014-08-31 | $14.85 10-Q · filed 2014-09-30 | ||||
| 2014-05-31 | $13.69 10-K · filed 2016-07-29 | ||||
| 2014-02-28 | $13.74 10-Q · filed 2014-04-04 | ||||
| 2013-11-30 | $13.39 10-Q · filed 2014-01-09 | ||||
| 2013-08-31 | $5.98 10-Q · filed 2013-09-30 | ||||
| 2013-05-31 | $10.61 10-K · filed 2015-07-30 | $15.91 10-K · filed 2013-07-30 | |||
| 2013-02-28 | $15.39 10-Q · filed 2013-03-28 | ||||
| 2012-11-30 | $14.43 10-Q · filed 2012-12-28 | ||||
| 2012-08-31 | $14.07 10-Q · filed 2012-09-28 | ||||
| 2012-05-31 | $8.29 10-K · filed 2014-07-30 | $12.44 10-K · filed 2012-07-30 | |||
| 2011-05-31 | $9.83 10-K · filed 2013-07-30 | ||||
| 2010-05-31 | $8.57 10-K · filed 2012-07-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Celldex Therapeutics, Inc. (CLDX) | United States | $2.471B | -9.72 |
| Intellia Therapeutics, Inc. (NTLA) | United States | $1.705B | -5.92 |
| ACHIEVE LIFE SCIENCES, INC. (ACHV) | United States | $0.806B | -5.88 |
| QuidelOrtho Corp (QDEL) | United States | $0.733B | -0.90 |
| Alpha Teknova, Inc. (TKNO) | United States | $0.500B | -18.12 |
| MYRIAD GENETICS INC (MYGN) | United States | $0.397B | -4.84 |
| Insight Molecular Diagnostics Inc. (IMDX) | United States | $0.129B | -3.90 |
| IMMUCELL CORP /DE/ (ICCC) | United States | $0.091B | 116.10 |
| BIOMERICA INC (BMRA) | United States | $0.011B | |
| Q/C TECHNOLOGIES, INC. (QCLS) | United States | $0.008B | -1.93 |